EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition ...
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €190.00. The company’s shares closed ...
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 190 Euro auf "Overweight" belassen. Analyst Richard Vosser sieht sich mit seiner ...
Die Merck Dividende wird für das vergangene Geschäftsjahr auf der aktuellen Hauptversammlung von Merck festgelegt. Der Vorstand von Merck macht dabei zunächst einen Vorschlag für die Merck ...
Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
In der Saison 2016/2017 verzichtete Merck auf sein erworbenes Namensrecht, um das Lebenswerk von Jonathan Heimes zu würdigen und die gemeinnützige Gesellschaft "DUMUSSTKÄMPFEN" zugunsten ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback